{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Renal+Tumors&page=12", "query": { "condition": "Renal Tumors", "page": 12 }, "page_size": 10 }, "pagination": { "page": 12, "page_size": 10, "total_count": 1797, "total_pages": 180, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Renal+Tumors&page=13&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Renal+Tumors&page=11&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T20:33:36.883Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00100906", "title": "Sequential ATRA Then IL-2 for Modulation of Dendritic Cells and Treatment of Metastatic Renal Cell Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Cancer" ], "interventions": [ { "name": "IL-2", "type": "DRUG" }, { "name": "ATRA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2004-08", "completion_date": "2013-07", "has_results": false, "last_update_posted_date": "2013-08-16", "last_synced_at": "2026-10-14T20:33:36.883Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00100906" }, { "nct_id": "NCT05725421", "title": "Transplantation of Reconstructed Renal Allografts Following Ex-Vivo Partial Nephrectomy", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Renal Cell Carcinoma" ], "interventions": [ { "name": "Donor Radical and Partial Nephrectomy", "type": "PROCEDURE" }, { "name": "Kidney Transplantation", "type": "PROCEDURE" }, { "name": "Laparoscopic Radical Nephrectomy", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 5, "start_date": "2026-09", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-08-06", "last_synced_at": "2026-10-14T20:33:36.883Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05725421" }, { "nct_id": "NCT03709771", "title": "Novel Mechanisms and Predictors of VEGF Receptor Inhibitor- or Immune Checkpoint Inhibitor-Associated Hypertension and Cardiovascular Disease", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Renal Cell Carcinoma", "Hypertension", "Melanoma", "Cancer" ], "interventions": [ { "name": "Ambulatory Blood Pressure Measurement", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Vanderbilt University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "40 Years to 75 Years" }, "enrollment_count": 2, "start_date": "2020-01-09", "completion_date": "2020-10-01", "has_results": true, "last_update_posted_date": "2024-01-12", "last_synced_at": "2026-10-14T20:33:36.883Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03709771" }, { "nct_id": "NCT01114230", "title": "A First in Man Study to Determine the Safety at Various Dose Levels of AGS-16M8F in Advanced Kidney Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Renal Cell Carcinoma", "Pharmacokinetics of AGS-16M8F" ], "interventions": [ { "name": "AGS-16M8F", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2010-08", "completion_date": "2012-11", "has_results": false, "last_update_posted_date": "2012-12-12", "last_synced_at": "2026-10-14T20:33:36.883Z", "location_count": 3, "location_summary": "Boston, Massachusetts • New York, New York • Seattle, Washington", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01114230" }, { "nct_id": "NCT04897321", "title": "B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pediatric Solid Tumor", "Osteosarcoma", "Rhabdomyosarcoma", "Neuroblastoma", "Ewing Sarcoma", "Wilms Tumor", "Adrenocortical Cancer", "Desmoplastic Small Round Cell Tumor", "Germ Cell Cancer", "Rhabdoid Tumor", "Clear Cell Sarcoma", "Hepatoblastoma", "Melanoma", "Carcinoma", "Malignant Peripheral Nerve Sheath Tumors", "Soft Tissue Sarcoma" ], "interventions": [ { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "MESNA", "type": "DRUG" }, { "name": "B7-H3 CAR T cells", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 48, "start_date": "2022-07-06", "completion_date": "2028-03-01", "has_results": false, "last_update_posted_date": "2026-05-19", "last_synced_at": "2026-10-14T20:33:36.883Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04897321" }, { "nct_id": "NCT01154452", "title": "Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adult Alveolar Soft Part Sarcoma", "Adult Angiosarcoma", "Adult Desmoplastic Small Round Cell Tumor", "Adult Epithelioid Hemangioendothelioma", "Adult Epithelioid Sarcoma", "Adult Extraskeletal Myxoid Chondrosarcoma", "Adult Extraskeletal Osteosarcoma", "Adult Fibrosarcoma", "Adult Leiomyosarcoma", "Adult Liposarcoma", "Adult Malignant Mesenchymoma", "Adult Malignant Peripheral Nerve Sheath Tumor", "Adult Rhabdomyosarcoma", "Adult Synovial Sarcoma", "Adult Unclassified Pleomorphic Sarcoma", "Chondrosarcoma", "Clear Cell Sarcoma of the Kidney", "Conjunctival Kaposi Sarcoma", "Dermatofibrosarcoma Protuberans", "Gastrointestinal Stromal Tumor", "Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor", "Metastatic Osteosarcoma", "Ovarian Sarcoma", "Recurrent Adult Soft Tissue Sarcoma", "Recurrent Adult Unclassified Pleomorphic Sarcoma of Bone", "Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor", "Recurrent Kaposi Sarcoma", "Recurrent Osteosarcoma", "Recurrent Uterine Corpus Sarcoma", "Small Intestine Leiomyosarcoma", "Stage III Adult Soft Tissue Sarcoma", "Stage III Uterine Sarcoma", "Stage IV Adult Soft Tissue Sarcoma", "Stage IV Uterine Sarcoma", "Unclassified Pleomorphic Sarcoma of Bone" ], "interventions": [ { "name": "Gamma-Secretase Inhibitor RO4929097", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Vismodegib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": "2010-06", "completion_date": "2015-02", "has_results": true, "last_update_posted_date": "2018-08-15", "last_synced_at": "2026-10-14T20:33:36.883Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01154452" }, { "nct_id": "NCT06630247", "title": "A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Cancers", "Solid Tumor Cancer", "Solid Tumor Malignancy", "Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer)", "Metastatic Solid Tumor", "Locally Advanced Solid Tumor", "Urothelial Cancer of Renal Pelvis" ], "interventions": [ { "name": "XL495", "type": "DRUG" }, { "name": "ADC cytotoxic agents", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Exelixis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2024-10-17", "completion_date": "2025-05-07", "has_results": false, "last_update_posted_date": "2025-06-25", "last_synced_at": "2026-10-14T20:33:36.883Z", "location_count": 10, "location_summary": "Denver, Colorado • New Haven, Connecticut • Washington D.C., District of Columbia + 6 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Jefferson", "state": "Louisiana" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06630247" }, { "nct_id": "NCT00003706", "title": "LY231514 in Treating Patients With Locally Advanced or Metastatic Solid Tumors and Varying Degrees of Kidney Function", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "pemetrexed disodium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The University of Texas Health Science Center at San Antonio", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "1998-04", "completion_date": "2002-06", "has_results": false, "last_update_posted_date": "2012-06-28", "last_synced_at": "2026-10-14T20:33:36.883Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003706" }, { "nct_id": "NCT00664326", "title": "A Phase II Uncontrolled Study of BAY73-4506 in Previously Untreated Patients With Metastatic or Unresectable RCC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Renal Cell" ], "interventions": [ { "name": "Regorafenib (Stivarga, BAY73-4506)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2008-04-30", "completion_date": "2019-04-02", "has_results": true, "last_update_posted_date": "2021-01-29", "last_synced_at": "2026-10-14T20:33:36.883Z", "location_count": 2, "location_summary": "Los Angeles, California • Houston, Texas", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00664326" }, { "nct_id": "NCT05842044", "title": "NSAID Use After Robotic Partial Nephrectomy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Cancer", "Renal Cancer", "Renal Neoplasm" ], "interventions": [ { "name": "Ketorolac", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Oxycodone", "type": "DRUG" }, { "name": "Hydromorphone", "type": "DRUG" }, { "name": "Ibuprofen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Miami", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 110, "start_date": "2023-09-15", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-09-24", "last_synced_at": "2026-10-14T20:33:36.883Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05842044" } ] }